Determined CEO Reclaims Her "Pink Pill" Empire for Women's Health

In November 2025, Cindy Eckert, the co-founder and CEO of Sprout Pharmaceuticals, is celebrating the resurgence of her company's signature product, the women's libido drug Addyi. After a decade-long battle to get the "little pink pill" approved by the FDA and then regain control of her company, Eckert's persistence has paid off as Addyi's popularity has soared in recent years.

Eckert's unwavering commitment to her "pink" brand and mission to destigmatize women's sexual health has been central to Addyi's journey. From the pink-themed decor of her home to the company's "unapologetically pink" office, Eckert has embraced the color as a symbol of her cause. This dedication has helped her weather the initial backlash and skepticism surrounding Addyi, as critics accused Sprout of trying to "medicalize" natural fluctuations in women's sexual desire.

However, a cultural shift in recent years, with growing openness around menopause, perimenopause, and women's sexual wellness, has turned the tide in Eckert's favor. Telehealth platforms and celebrity endorsements have further chipped away at the stigma, and regulatory changes have made Addyi more accessible to patients. This year, Sprout is on track to double its revenue, and Eckert is working on new public campaigns to address the lack of parity in how insurers cover women's health treatments compared to men's.

Eckert's unwavering determination to bring Addyi to market and her refusal to give up, even after setbacks, have been key to the drug's resurgence. As she navigates Sprout's second chapter, Eckert remains committed to her mission of empowering women and destigmatizing their sexual health needs.